The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PV

The MPN Hub were pleased to speak to Jean-Jacques Kiladjian, University of Paris, Paris, FR, during the 61st American Society of Hematology (ASH) meeting in Orlando, US. Based on the PROUD-PV/CONTINUATION-PV studies, we asked: What are the benefits of ropeginterferon alpha-2b for the treatment of polycythemia vera?

Jean-Jacques Kiladjian discusses the results of the phase III, randomized, PROUD-PV and its extension study, CONTINUATION-PV, in patients with polycythemia vera in need of a cytoreductive treatment such as the long-acting ropeginterferon alpha-2b. He explains the response rates, clinical benefits and superiority of the ropeginterferon alpha-2b treatment against the comparator arm.

PROUD-PV/CONTINUATION-PV studies: benefits of ropeg IFN alfa-2b for the treatment of PV

Share: